A decade of waiting, then answers in forty-five minutes
For generations, women in England and Wales have carried the weight of an unnamed illness, waiting nearly a decade on average before endometriosis could be confirmed — a delay that allowed pain to deepen and disease to progress. This week, the National Institute for Health and Care Excellence approved two new rapid diagnostic tests for NHS use, offering the possibility that what once took years might now be resolved in weeks. The decision reflects a broader reckoning with how medicine has historically responded to women's pain, and marks a tentative but meaningful step toward closing that gap.
- Women with endometriosis have waited an average of nine years for diagnosis — eleven for those from ethnically diverse communities — while chronic pain quietly dismantled their work, relationships, and mental health.
- The only definitive diagnostic tool has been surgical laparoscopy, an invasive procedure requiring hospital capacity, while ultrasound and MRI frequently failed to detect the condition at all.
- NICE has now approved two non-invasive tests — a saliva-based microRNA analysis and a 45-minute gut sensor procedure — that can be administered in primary care and deliver results before a woman leaves the room.
- The approval is conditional: both tests will operate on a three-year NHS trial, with permanent status dependent on real-world evidence of effectiveness — and one candidate test was rejected outright for insufficient data.
- Faster diagnosis not only means earlier treatment and less suffering, but could also relieve pressure on overstretched surgical and gynaecological services across the NHS.
For nearly a decade, women across England and Wales have lived with a question their bodies could not stop asking. The average diagnosis of endometriosis takes nine years and four months — eleven for women from ethnically diverse communities. During that time, tissue grows where it should not, reshaping daily life through pain, disrupted relationships, and careers held hostage to a body no one can yet explain. One in ten women of reproductive age live with the condition, yet the medical system has long treated its diagnosis as something to be solved slowly, through imaging that often misses it or surgery that confirms it only after years of waiting.
This week, the National Institute for Health and Care Excellence approved two new tests for NHS use in England and Wales. The first, Endotest, requires only a saliva sample — a woman spits into a tube, and laboratory technicians search for microRNAs, biological markers that signal the presence of endometriosis. The second, EndoSure, asks women to fast briefly, then drink water while wearing sensor pads on their abdomen; the device reads electrical patterns in the gut and delivers results within forty-five minutes, before the woman has left the clinic. Neither test replaces clinical judgment or imaging entirely, but both are designed for the moment that has historically led nowhere: when symptoms are clear but initial exams are inconclusive.
The approval carries a condition. NICE has authorised both tests for three years on a trial basis, during which the NHS will gather real-world evidence of their effectiveness. Permanent approval depends on what that evidence shows. A third test, DotEndo, did not meet the threshold and was sent back for further research.
For the millions of women currently in the long middle of their wait, the decision represents something more than a clinical update. It is not a cure — endometriosis remains a chronic condition without one. But it is the difference between naming what is happening to your body and being told to live with the mystery. It is the difference between beginning treatment now and beginning it five years from now, when the disease has had more time to take hold. The tests are expected to be available on the NHS within weeks.
For nearly a decade, women across England and Wales have waited for answers to a question their bodies were screaming: what is wrong with me? The average diagnosis of endometriosis takes nine years and four months. For women from ethnically diverse communities, it stretches to eleven years. During that time, tissue that should exist only in the womb lining grows elsewhere—on the ovaries, fallopian tubes, bowel, bladder—causing pain that reshapes a life. Periods become ordeals. Sex becomes something to dread. Work becomes a negotiation with your own body. And still, no one can tell you why.
One in ten women of reproductive age live with endometriosis. The condition is common enough that nearly every woman knows someone suffering through it, yet the medical system has treated diagnosis as a puzzle to be solved slowly, through ultrasounds that miss it, MRI scans that inconclusive, or laparoscopy—surgery where a camera is threaded through an incision in the abdomen—the only way to be truly certain. The human cost of these delays is not abstract. Chronic pain erodes relationships, derails careers, compounds mental health struggles. Women describe a decade of being told they're imagining things, that period pain is normal, that they should just manage it better. By the time diagnosis arrives, the disease has often progressed to a point where treatment is harder.
This week, the National Institute for Health and Care Excellence approved two new tests for NHS use in England and Wales, a decision that could collapse that timeline from years to weeks. The first, called Endotest, requires only a saliva sample. A woman spits into a tube, sends it to a laboratory, and technicians search for microRNAs—tiny biological markers that signal the presence of endometriosis. Results come back to her GP or healthcare provider, who can then move forward with treatment or further investigation. The second test, EndoSure, works differently. Women fast for six to eight hours, then drink water until comfortably full while wearing sensor pads on their abdomen. The device measures electrical signals in the gut, detecting patterns consistent with endometriosis. The entire procedure takes forty-five minutes. Results are ready before the woman leaves.
Dr. Anastasia Chalkidou, who directs the healthtech programme at NICE, framed the approval as a fundamental shift in how the health system responds to women's pain. The delays that have defined endometriosis diagnosis—the years of suffering, the disease progression that makes treatment more difficult—stem partly from the tools available. Ultrasound and MRI are not always reliable. Surgery, while definitive, is invasive and requires hospital capacity. These new tests offer something different: non-invasive, rapid, accessible in primary care. They do not replace clinical judgment or imaging entirely. Rather, they are designed for women whose symptoms suggest endometriosis but whose initial exams and imaging have been inconclusive or negative. In those cases, a saliva test or a forty-five-minute sensor reading can provide the clarity that currently requires waiting months or years.
The approval comes with a condition. NICE has authorized the tests for three years on a trial basis. During that period, the NHS will collect evidence on how well they actually work in real practice, not just in research settings. If the data supports their effectiveness, permanent approval will follow. If not, they may be withdrawn. A third test, called DotEndo, did not clear this threshold; NICE determined it needed more research before it could recommend NHS use.
Dr. Gail Busby, a consultant gynaecologist at Manchester University NHS Foundation Trust, called the approval a gamechanger. Earlier diagnosis means earlier treatment, which means less suffering and better outcomes. But there is another dimension to her comment worth sitting with: an earlier diagnosis also frees up surgical slots and appointments for other patients waiting for care. The backlog in women's health services is real. Endometriosis diagnosis has consumed enormous amounts of NHS time and resources precisely because it has been so slow and difficult to confirm. Faster diagnosis, paradoxically, could ease pressure on the entire system.
For the millions of women currently waiting—some of them years into their wait—the approval represents a possible end to a particular kind of medical limbo. It is not a cure. Endometriosis remains a chronic condition without a cure. But it is the difference between knowing and not knowing, between being able to name what is happening to your body and being told to live with the mystery. It is the difference between starting treatment now and starting it in five years, when the disease has had time to entrench itself. The tests will be available on the NHS within weeks. The real measure of their impact will come in the months and years ahead, as women who have waited a decade finally get answers.
Notable Quotes
These tests are a gamechanger because they give us answers much earlier, without the need for invasive surgery, and that means we can start the right treatment sooner.— Dr. Gail Busby, consultant gynaecologist at Manchester University NHS Foundation Trust
A diagnosis of endometriosis can for some women take the best part of a decade, with the UK average standing at nine years and four months, and rising to 11 years for those from ethnically diverse communities.— Dr. Anastasia Chalkidou, NICE's healthtech programme director
The Hearth Conversation Another angle on the story
Why has endometriosis diagnosis taken so long? Is it a rare condition?
It's not rare at all—one in ten women of reproductive age have it. The problem is that the tests we've relied on—ultrasound, MRI, surgery—are either unreliable or invasive. There's no quick way to confirm it without cutting into someone.
So these new tests are faster. But are they accurate?
That's the question NICE is asking. They've approved them for three years while the NHS collects real-world evidence. If they work as well in practice as they do in trials, they become permanent. If not, they get pulled.
What changes for a woman the moment she gets a diagnosis?
Everything, potentially. She can start treatment—medication, surgery if needed, lifestyle changes. But more than that, she stops being told she's imagining things. She has a name for her pain. She can plan her life around it instead of being blindsided by it.
The article mentions women from ethnic minorities wait even longer. Why?
The source doesn't explain the mechanism, but the data is stark—eleven years instead of nine. It suggests systemic barriers: maybe less access to specialists, maybe their symptoms are taken less seriously, maybe language or cultural factors create friction in the system.
If these tests work, what happens to the surgical waiting lists?
They should shrink. Right now, laparoscopy is the gold standard for confirmation, and it requires an operating room and a surgeon. If a saliva test or a forty-five-minute sensor reading can do the job, that frees up surgical capacity for other patients.
Is this a cure?
No. Endometriosis has no cure. This is about diagnosis—knowing what you have so you can treat it. But knowing sooner means treating sooner, which means less time for the disease to worsen.